GlassScriptPhysician profile
Nipun Chhabra
NPI 1861687584
$177,890.73
in general payments reported to CMS, 2019-2025
21 companies · $9,202 in 2025
The $9,202 reported for 2025 was more than what 97% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $11K · 2021: $22K · 2022: $33K · 2023: $52K · 2024: $38K · 2025: $9,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $14K · Food and Beverage: $3,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,294.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,993.00 |
| Travel and Lodging | $14,127.17 |
| Food and Beverage | $3,726.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $107,262.09 | 2019-2025 | Scopis Ent, Xpress Loprofile, Clarifix Cryotherapy Device |
| Medtronic, INC. | $40,655.28 | 2021-2024 | Propel, Sinuva, Straightshot |
| Intersect Ent, INC. | $24,372.15 | 2019-2022 | |
| Karl Storz Endoscopy-America | $4,091.00 | 2021-2023 | Rhinoforce, N.A. |
| Regeneron Healthcare Solutions, INC. | $367.52 | 2021-2024 | Dupixent, Libtayo |
| Aerin Medical INC. | $195.66 | 2020-2024 | |
| Acclarent, INC | $155.55 | 2023 | Trudi Nav Cable |
| Baxter Healthcare | $138.04 | 2025 | Tisseel |
| Medtronic USA, INC. | $130.21 | 2019 | |
| Glaxosmithkline, LLC. | $117.90 | 2022-2024 | Nucala |
| Optinose US, INC. | $98.69 | 2021-2024 | |
| Phadia US INC. | $57.74 | 2020-2023 | Immunocap |
| Neurent Medical Limited | $51.34 | 2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Novartis Pharmaceuticals Corporation | $39.27 | 2021 | |
| Integra Lifesciences Corporation | $34.74 | 2024 | Integra, Microfrance, Integra Duo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $30.11 | 2021-2022 | |
| Olympus America INC. | $25.51 | 2022 | |
| Supreme Orthopedic Systems, LLC | $24.31 | 2023 | |
| Merck Sharp & Dohme LLC | $18.56 | 2022 | |
| Smith+Nephew, INC. | $13.32 | 2022 | |
| Teleflex LLC | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nipun Chhabra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.